Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Keytruda

- PMLiVE

Merck shares positive results for Keytruda in phase 3 bladder cancer study

Over 82,000 people in the US will be be diagnosed with bladder cancer in 2023

- PMLiVE

Pfizer’s Litfulo approved by EC for adults and adolescents with severe alopecia areata

The autoimmune disease affects approximately 147 million people globally

EU flag

EC approves Otsuka and Astex’s Inaqovi for acute myeloid leukaemia

Inaqovi is the first oral hypomethylating agent approved for this patient population

- PMLiVE

BMS presents positive six-year results for Opdivo/Yervoy combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

NIHR awards £2.3m for AI study to improve radiotherapy for lung cancer

The AI tool is expected to help doctors plan each patient’s radiotherapy treatment

- PMLiVE

IO Biotech announces new data supporting its therapeutic cancer vaccine

The vaccine showed promise when used in combination with Merck & Co’s Keytruda

- PMLiVE

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

The drug is now the first ALK inhibitor to show disease-free survival benefit in this patient population

Biomarin

BioMarin announces first patient dosed with haemophilia A gene therapy in Europe

The therapy was granted conditional marketing authorisation by the EC in August 2022

- PMLiVE

Merck receives EC approval for Keytruda combination in gastric cancer

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Roche’s spinal muscular atrophy therapy Evrysdi approved by EC for newborns

The neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Pfizer’s RSV vaccine granted EC approval to protect infants and older adults

The decision allows Abrysvo to be given to those who are 24 to 36 weeks into their pregnancy

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links